155 related articles for article (PubMed ID: 34854745)
1. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
Waisman Malaret AJ; Chang P; Zhu K; Zheng Y; Newcomb LF; Liu M; McKenney JK; Brooks JD; Carroll P; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Lin DW; Wagner AA
J Urol; 2022 Apr; 207(4):805-813. PubMed ID: 34854745
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract][Full Text] [Related]
3. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
4. Risk of Biochemical Recurrence in Patients With Grade Group 1 Prostate Cancer With Extraprostatic Extension Treated With Radical Prostatectomy.
Rezaee ME; Pallauf M; Fletcher SA; Han M; Pavlovich CP; Cornelia Ding CK; Epstein JI; Allaf ME; Trock BJ; Singla N
J Urol; 2024 Mar; 211(3):407-414. PubMed ID: 38109699
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Roobol MJ; Helleman J; van Leenders GJLH
Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
Perera M; Jibara G; Tin AL; Haywood S; Sjoberg DD; Benfante NE; Carlsson SV; Eastham JA; Laudone V; Touijer KA; Fine S; Scardino PT; Vickers AJ; Ehdaie B
Eur Urol Focus; 2023 Jul; 9(4):662-668. PubMed ID: 36566100
[TBL] [Abstract][Full Text] [Related]
7. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
8. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
[TBL] [Abstract][Full Text] [Related]
9. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
11. Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance.
Audenet F; Rozet F; Resche-Rigon M; Bernard R; Ingels A; Prapotnich D; Sanchez-Salas R; Galiano M; Barret E; Cathelineau X
Clin Genitourin Cancer; 2017 Dec; 15(6):e907-e913. PubMed ID: 28522288
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z; Gleave ME; Kunju P; Lance RS; McKenney JK; Meng MV; Nicolas MM; Sanda MG; Simko J; So A; Tretiakova MS; Troyer DA; True LD; Vakar-Lopez F; Virgin J; Wagner AA; Wei JT; Zheng Y; Nelson PS; Lin DW;
J Urol; 2016 Feb; 195(2):313-20. PubMed ID: 26327354
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis.
Chandrasekar T; Bowler N; Schneider A; Goldberg H; Mark JR; Trabulsi EJ; Lallas CD; Gomella LG
Urology; 2021 Sep; 155():101-109. PubMed ID: 34186134
[TBL] [Abstract][Full Text] [Related]
14. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
Wissing M; Brimo F; Chevalier S; Scarlata E; McKercher G; O'Flaherty A; Aprikian S; Thibodeau V; Saad F; Carmel M; Lacombe L; Têtu B; Ekindi-Ndongo N; Latour M; Trudel D; Aprikian A
BJU Int; 2019 Apr; 123(4):624-631. PubMed ID: 30113732
[TBL] [Abstract][Full Text] [Related]
15. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
Chappidi MR; Bell A; Cowan JE; Greenberg SA; Lonergan PE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2022 May; 207(5):1001-1009. PubMed ID: 34981949
[TBL] [Abstract][Full Text] [Related]
16. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.
Kato M; Hirakawa A; Sato H; Hanazawa R; Naito Y; Tochigi K; Sano T; Ishida S; Funahashi Y; Fujita T; Matsukawa Y; Hattori R; Tsuzuki T
Int J Clin Oncol; 2021 Apr; 26(4):764-769. PubMed ID: 33385274
[TBL] [Abstract][Full Text] [Related]
17. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.
Diolombi ML; Epstein JI
BJU Int; 2017 Jun; 119(6):872-878. PubMed ID: 27496532
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.
Kinnaird A; Yerram NK; O'Connor L; Brisbane W; Sharma V; Chuang R; Jayadevan R; Ahdoot M; Daneshvar M; Priester A; Delfin M; Tran E; Barsa DE; Sisk A; Reiter RE; Felker E; Raman S; Kwan L; Choyke PL; Merino MJ; Wood BJ; Turkbey B; Pinto PA; Marks LS
J Urol; 2022 Apr; 207(4):823-831. PubMed ID: 34854746
[TBL] [Abstract][Full Text] [Related]
19. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
Baraban E; Erak E; Fatima A; Akbari A; Zhao J; Fletcher SA; Bhanji Y; de la Calle CM; Mamawala M; Landis P; Macura KJ; Pavlovich CP; Epstein JI
J Urol; 2023 Jul; 210(1):99-107. PubMed ID: 37042826
[TBL] [Abstract][Full Text] [Related]
20. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Cooley LF; Emeka AA; Meyers TJ; Cooper PR; Lin DW; Finelli A; Eastham JA; Logothetis CJ; Marks LS; Vesprini D; Goldenberg SL; Higano CS; Pavlovich CP; Chan JM; Morgan TM; Klein EA; Barocas DA; Loeb S; Helfand BT; Scholtens DM; Witte JS; Catalona WJ;
J Urol; 2021 Nov; 206(5):1147-1156. PubMed ID: 34503355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]